Recently, we learned from Rizhao People’s Hospital in Shandong Province that Sun Liang, the first fat 22-year-old boy in China, passed away due to a series of complications caused by obesity. Since fatty liver is mostly associated with obesity, the number of patients has increased as the number of obese people has grown. The incidence of simple fatty liver/non-alcoholic steatohepatitis (collectively called “non-alcoholic fatty liver disease”, abbreviated as NAFLD) in developed regions of China, such as North, Shanghai and Guangzhou, is as high as 15%, and the ultimate cause of death is cardiovascular disease, and recently the combination of liver fibrosis, liver cirrhosis and other liver diseases caused by death also increased again, and even liver tumors. In addition to long-term alcohol consumption leading to alcoholic cirrhosis, NAFLD advanced liver disease, the most important cause of cirrhosis in China is the well-known chronic hepatitis B virus infection, chronic hepatitis, liver fibrosis, cirrhosis or liver cancer is what we usually call the “three-step process”, due to advanced cirrhosis, liver cancer and other end-stage Liver disease is incurable and death is the result. Early detection of chronic liver disease An analysis of the advantages and disadvantages of mainstream liver disease detection methods The clinical and pathological evolution of most chronic liver diseases, especially chronic viral hepatitis, shows that liver fibrosis is a necessary stage in the development of chronic liver disease to cirrhosis. In other words, all chronic liver diseases cause liver damage and lead to liver fibrosis. If liver fibrosis caused by chronic liver disease is not treated in a timely manner, it can develop into cirrhosis or even liver cancer, which can eventually lead to death. As long as the degree of liver fibrosis in patients with chronic liver disease can be accurately diagnosed, it will help clinicians determine the progress of the patient’s disease and carry out targeted treatment. What clinical tests are available to check and diagnose liver fibrosis, cirrhosis and fatty liver? Professor Chen Youpeng listed the following points. First, liver puncture biopsy is the internationally recognized “gold standard”. The disadvantages are, first, invasive invasive testing, small sampling area, a certain sampling error, and uncertainty in pathological diagnosis; second, it can sometimes lead to serious complications, such as bleeding; third, it is not easy to repeat. So ultimately, many patients are reluctant to accept this damaging examination, especially in our country this phenomenon is more obvious. Second, B ultrasound and CT examination, which has been used in the clinic for a longer time, is now widely used. The advantage is that it can roughly determine the fatty liver and its degree, suggest whether it has developed into obvious cirrhosis, and clarify the presence of intrahepatic occupying lesions. The disadvantage of CT is that it does not indicate the degree of inflammation and liver fibrosis, unless there is portal hypertension. And this test is more expensive. Serological tests are commonly referred to as blood tests for liver fibrosis. At present, there is no reliable serum indicators to diagnose, generally based on the doctor’s personal experience, combined with a number of indicators of laboratory tests, comprehensive consideration and evaluation. The four items of liver fibrosis (type III procollagen, type IV collagen, laminin, and hyaluronidase) currently examined in hospitals, which are diagnostic indicators of the degree of liver fibrosis, are not very specific, have low accuracy, and are susceptible to the interference of inflammation, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST); and have relatively low clinical acceptance. New means of liver disease examination: FibroScan-CAP is painless, non-invasive, intuitive and comprehensive Is there a better means of detection for early detection of hidden liver disease? Of course there is. According to Professor Chen Youpeng, this method is the latest generation of Echosens’ integrated diagnostic instrument for liver fibrosis and fatty liver (FibroScan-CAP), a simple, accurate, repeatable and quantitative analysis test. Liver stiffness is an important indicator of the degree of liver fibrosis, which gradually increases as the degree of liver fibrosis deepens. While FibroScan-CAP provides early quantitative measurement of liver stiffness through the patented VCTE technique, it also enables quantitative diagnosis of fatty liver through the patented CAP technique for the quantitative diagnosis of hepatic steatosis. Compared to ultrasound, which can only diagnose qualitatively through images and at least 30% steatosis before diagnosis, FibroScan-CAP not only achieves quantitative diagnosis with precise numerical display, but also diagnoses fatty liver as long as the steatosis reaches 10%, truly achieving early screening and diagnosis of fatty liver. The advantages of this test are: 1, non-invasive and painless: no blood collection, rapid and non-invasive, and can be repeated many times; 2, intuitive and comprehensive: the degree of liver fibrosis and steatosis is directly reflected by quantitative figures, and the volume of liver tissue sampled is 100 times larger than that of liver puncture samples, reflecting the degree of liver health more comprehensively; 3, fast and easy: the whole process takes only 2 to 5 minutes, and the test results are presented immediately; 4, widely applicable. It can be used for screening, diagnosis and monitoring of early, middle and late stages of fatty liver. 5.Inexpensive: the cost is less than $180 once. Mainly applicable to (indications) the following disease examination: 1, various chronic liver disease, liver fibrosis, cirrhosis, fatty liver examination. 2, the assessment of chronic hepatitis C before treatment, the presence of cirrhosis. 3, obesity, overweight and age 40 years or older, as well as the assessment of pre-existing chronic diseases, especially diabetes, coronary heart disease, hypertension, stroke (cerebrovascular accident), elevated lipids or hyperuricemia, and the presence of combined fatty liver. 4. For long-term alcohol drinkers, to understand the presence of alcoholic cirrhosis.